Literature DB >> 1425889

Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus.

T S Trovik1, R Jaeger, R Jorde, O Ingebretsen, G Sager.   

Abstract

In the present study equilibrium dialysis has been used to determine the degree of protein binding of the catecholamines adrenaline and noradrenaline and the adrenergic receptor blockers, prazosin and propranolol in diabetics. The binding of the catecholamines in plasma from Type I and II diabetic patients was not significantly different from that of healthy subjects. The ratio of the bound and free catecholamine concentrations was correlated with the level of albumin (HSA). Significantly reduced protein binding of prazosin was observed in Type I and II diabetic subjects compared to healthy volunteers. The binding of propranolol was significantly reduced in Type I patients. The ratios between the bound and unbound concentrations of prazosin and propranolol were significantly correlated with the levels of alpha 1-acid glycoprotein (AAG). The results suggest that non-enzymatic glycosylation of plasma proteins may increase the unbound fraction of the adrenergic blockers prazosin and propranolol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425889     DOI: 10.1007/bf02333020

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Plasma noradrenaline increases with age.

Authors:  M G Ziegler; C R Lake; I J Kopin
Journal:  Nature       Date:  1976-05-27       Impact factor: 49.962

Review 2.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

3.  Prazosin protein binding in health and disease.

Authors:  P Rubin; T Blaschke
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

4.  Increased levels of acute-phase serum proteins in diabetes.

Authors:  D E McMillan
Journal:  Metabolism       Date:  1989-11       Impact factor: 8.694

5.  Prazosin binding to human alpha 1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid.

Authors:  F Brunner; W E Müller
Journal:  J Pharm Pharmacol       Date:  1985-05       Impact factor: 3.765

6.  Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy.

Authors:  R D Hoeldtke; G Boden; C R Shuman; O E Owen
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

7.  Beta-adrenoceptor regulation in insulin-dependent diabetes mellitus.

Authors:  G Sager; L Slørdal; N E Huseby; J Florholmen
Journal:  Scand J Clin Lab Invest       Date:  1991-05       Impact factor: 1.713

8.  Abnormal serum protein binding of acidic drugs in diabetes mellitus.

Authors:  F Ruiz-Cabello; S Erill
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

9.  Differences in the serum protein binding of prazosin in man and rat.

Authors:  O Dale; O G Nilsen
Journal:  Biochem Pharmacol       Date:  1984-06-01       Impact factor: 5.858

10.  Catecholamine binding and concentrations in acute phase plasma after surgery.

Authors:  G Sager; T Trovik; L Slørdal; R Jaeger; P S Prytz; J Brox; O Reikerås
Journal:  Scand J Clin Lab Invest       Date:  1988-09       Impact factor: 1.713

View more
  5 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

3.  Binding and clearance of radioactive adrenaline and noradrenaline in sheep blood.

Authors:  S M El-Bahr; H Kahlbacher; M Patzl; R G Palme
Journal:  Vet Res Commun       Date:  2006-05       Impact factor: 2.459

4.  Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness.

Authors:  T S Trovik; R Jaeger; R Jorde; G Sager
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

5.  Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.

Authors:  Alok S Tripathi; Papiya M Mazumder; Anil V Chandewar
Journal:  J Diabetes Metab Disord       Date:  2014-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.